Treatment News : Gilead Sciences, Task Force Agree to ADAP Price Discount for Stribild

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Treatment News » September 2012

Most Popular Links
Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to


September 6, 2012

Gilead Sciences, Task Force Agree to ADAP Price Discount for Stribild

The AIDS Drug Assistance Program (ADAP) purchase price for the newly approved fixed-dose combination tablet Stribild will be substantially lower than the announced $28,500 wholesale acquisition cost (WAC), as a result of a new pricing agreement reached between Gilead Sciences and the ADAP Crisis Task Force (ACTF). According to a news announcement by the National Alliance of State & Territorial AIDS Directors (NASTAD), the national association that convened ACTF, the agreement also continues a price freeze on all Gilead’s antiretrovirals purchased by ADAPs through 2013. “The fiscal crises many ADAPs continue to experience require ongoing and new commitments on the part of pharmaceutical companies as well as federal and state governments,” explained Dwayne Haught, manager of the Texas ADAP and a founding member of the ACTF.  “We thank Gilead for agreeing to price this new medication for ADAPs at a point that will allow access to it for clients without adversely impacting ADAP budgets.”

To read the NASTAD news announcement, click here.

Search: stribild, adap, price, task force, nastad

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Hide comments

Previous Comments:

  comments 1 - 2 (of 2 total)    

Brian, Beantown, 2012-11-24 09:23:34
Neglected by almost all advocacy groups much to my dismay, other than the HIVandHepatitis quaterly byGHMC is Gilead's discontinuation of 100 percent cure across all 3 genotypes of Hep C (type 1, 2, and 3). Rather than use GS7977 (sobufesvir)with BMS dataclasvir and cure everyone, Gilead finds it far wiser to focus not on compassionate access, or curing those it can cure now by going to Phase 3, but rather they are pretending they will go forward, SVR24 all cured-no phase 3? Profits too low-death

Frederick Wright, Coachella Valley, 2012-09-13 17:40:51
OK.. Thank you that was hard to type, for it is like thanking a use car salmen for taking my money for a used car or better yet a lawyer . Yes, I can see it now, the car salman saying "you are so lucky for my boss lower the price by 1000 dollars, just for you and then I look in my hand and all my money is gone, but I have a used car. Ok again , Thank you Gilead.I praying to Jesus for you and yours for we most remember their will be a day of true reconcilation.

comments 1 - 2 (of 2 total)    

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.